Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Brazil / NCT07789678
Starting soon Observational

Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in Brazil

NCT07789678 · tracked via the Priya Life Science Brazil tracker
Sponsor
Latin American Cooperative Oncology Group
Phase
Observational
Started
2026-09
Last updated
2026-09-04

Condition(s) studied

Diffuse GliomaIDH-mutant Gliomas

Study summary

This is a real-world, retrospective, non-interventional, single-arm, multi-center Brazilian study that will include patients diagnosed with IDH-mutant diffuse glioma in Brazil from 2021. Eligible patients will be included in this study to have their medical charts data collected by site personnel. Included patients won´t be requested to attend protocol-specific visits and treatment decisions and disease management will be at the investigator's discretion

Eligibility

Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female patients (aged 12 years or older); * Histologically confirmed diagnosis of diffuse glioma from 2021; * Confirmed IDH mutation identified by IHC or PCR/NGS; * Willing and able to provide written informed consent, applicable to living patients. In case of patients \<18 years of age, their legal guardians should provide an written informed consent Exclusion Criteria: Since the study is observational, there are no extensive Exclusion Criteria, but the following criteria excludes patients from the study to ensure data collected by be analyzed from a broader context and compared to other studies of this kind: * Patients without medical record available (lost, empty or irretrievable clinical information). * Living patients and/or legal guardians of patients \<18 years of age who did not accept or withdrew their consent from the study.

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
IESG Instituto de Ensino da Saúde e Gestão Salvador Estado de Bahia
Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel (Oncoclínicas) Salvador Estado de Bahia
ÉTICA Clínica AMO - Assistência Multidisciplinar em Oncologia Salvador Estado de Bahia
OncoStar Rede D'or DF Brasília Federal District
Oncocentro de Minas Gerais (Oncoclínicas) Belo Horizonte Minas Gerais
INCA - Instituto Nacional de Câncer Rio de Janeiro Rio de Janeiro
Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ) Rio de Janeiro Rio de Janeiro
Futtura Oncologia - Hub de Pesquisa Clínica Porto Alegre Rio Grande do Sul
Hospital Sírio-Libanês SP São Paulo São Paulo
BP - A Beneficência Portuguesa de São Paulo São Paulo São Paulo
GRAACC - Grupo de Apoio ao Adolescente e à Criança com Câncer São Paulo São Paulo
HIAE - Hospital Israelita Albert Einstein São Paulo São Paulo

More Latin American Cooperative Oncology Group trials in Brazil

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer Active, not recruiting
Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Starting soon
A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America Active, not recruiting
Oncogeriatric Screening and Evaluation Program Starting soon
Validation of the G8 Screening Tool for Prognostic Assessment of Frailty and Early Mortality in Elderly Individuals With Cancer: Prospective Cohort Study in Brazil Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07789678 on ClinicalTrials.gov ↗ ← All trials in Brazil